Oncotype DX复发评分是否会影响早期乳腺癌患者的治疗管理？
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
作者信息
Asad Juhi, Jacobson Allyson F, Estabrook Alison, Smith Sharon Rosenbaum, Boolbol Susan K, Feldman Sheldon M, Osborne Michael P, Boachie-Adjei Kwadwo, Twardzik Wendy, Tartter Paul I
机构信息
Division of Breast Surgery, St. Luke's-Roosevelt Hospital Center, New York, NY, USA; Division of Breast Surgery, Beth Israel Medical Center, New York, NY, USA.
出版信息
Am J Surg. 2008 Oct;196(4):527-9. doi: 10.1016/j.amjsurg.2008.06.021.
BACKGROUND
Oncotype DX is a 21-gene assay that calculates a risk of distant recurrence in women with estrogen-receptor-positive, lymph node-negative breast cancer. The purpose of this study was to determine whether the results of Oncotype DX influence the decision to administer chemotherapy.
METHODS
A retrospective study was performed on 85 consecutive patients with estrogen-receptor-positive, lymph node-negative breast cancer who had an Oncotype DX recurrence score (RS) obtained. Tumor size, tumor grade, and treatment were then compared within each risk category. Statistical analysis was performed using STATA software.
RESULTS
Tumors that were high grade and Her-2/neu positive more frequently had a high RS. Treatment was changed as a result of Oncotype DX in 44% of patients.
CONCLUSIONS
Oncotype DX RS is significantly related to tumor grade and Her2/neu status. In this study, the treatment of 44% of patients was altered as a consequence of Oncotype DX RS.
背景
Oncotype DX是一种21基因检测方法，用于计算雌激素受体阳性、淋巴结阴性乳腺癌女性远处复发的风险。本研究的目的是确定Oncotype DX的结果是否会影响化疗决策。
方法
对85例连续的雌激素受体阳性、淋巴结阴性乳腺癌患者进行回顾性研究，这些患者均获得了Oncotype DX复发评分（RS）。然后在每个风险类别中比较肿瘤大小、肿瘤分级和治疗情况。使用STATA软件进行统计分析。
结果
高级别且Her-2/neu阳性的肿瘤更常具有高RS。44%的患者因Oncotype DX改变了治疗方案。
结论
Oncotype DX RS与肿瘤分级和Her2/neu状态显著相关。在本研究中，44%患者的治疗因Oncotype DX RS而改变。
Zotero 插件